PharmaDepth

Company profile

ABBVIE INC.

NYSE:ABBVBiotechnology: Pharmaceutical Preparations

Drug pipeline (229)

AssetStageRevenueTrialsStatus
SKYRIZIapproved$5.5BQ2 20260—
SKYRIZIapproved$5.5BQ2 20260—
RINVOQapproved$2.5BQ2 202660approved
VRAYLARapproved$1.1BQ2 20260—
BOTOXapproved$1.0BQ2 20260—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (1915)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT03777059phase3completed2018-12-142020-06-19Allergan12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
NCT00457795phase4completed2006-12-012009-02-01Allergan24-hour IOP-lowering Effect of Brimonidine 0.1%
NCT02472626phase1_2withdrawn2015-12-012016-07-01Wake Forest University Health Sciences6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT01162421phase4completed2010-09-012015-07-01AbbVie (prior sponsor, Abbott)A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis
NCT03573297phase3completed2018-06-152022-09-05AbbVieA Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features

FDA applications (165)

ApplicationApprovedTypeApplicantProducts
BLA 7614602026-05-27BLAABBVIE INC.
BLA 7613842025-05-14BLAABBVIE INC.
NDA 2179062025-02-07NDAABBVIE INC
NDA 2169622024-10-16NDAABBVIE INC
NDA 2183472024-04-26NDAABBVIE INC